312 related articles for article (PubMed ID: 34360795)
1. Autoimmune Responses in Oncology: Causes and Significance.
Bareke H; Juanes-Velasco P; Landeira-Viñuela A; Hernandez AP; Cruz JJ; Bellido L; Fonseca E; Niebla-Cárdenas A; Montalvillo E; Góngora R; Fuentes M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360795
[TBL] [Abstract][Full Text] [Related]
2. Adverse events induced by immune checkpoint inhibitors.
Perdigoto AL; Kluger H; Herold KC
Curr Opin Immunol; 2021 Apr; 69():29-38. PubMed ID: 33640598
[TBL] [Abstract][Full Text] [Related]
3. Understanding adverse events of immunotherapy: A mechanistic perspective.
Burke KP; Grebinoski S; Sharpe AH; Vignali DAA
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33601411
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Khan S; Gerber DE
Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
[TBL] [Abstract][Full Text] [Related]
5. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
von Itzstein MS; Khan S; Gerber DE
Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387
[TBL] [Abstract][Full Text] [Related]
6. The crossroads between cancer immunity and autoimmunity: antibodies to self antigens.
Benvenuto M; Mattera R; Masuelli L; Tresoldi I; Giganti MG; Frajese GV; Manzari V; Modesti A; Bei R
Front Biosci (Landmark Ed); 2017 Mar; 22(8):1289-1329. PubMed ID: 28199204
[TBL] [Abstract][Full Text] [Related]
7. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
8. Predicting immunotherapy response through genomics.
Cormedi MCV; Van Allen EM; Colli LM
Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to tumor-associated antigens: reporters from the immune system.
Tan EM; Zhang J
Immunol Rev; 2008 Apr; 222():328-40. PubMed ID: 18364012
[TBL] [Abstract][Full Text] [Related]
10. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
12. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
13. Understanding and treating the inflammatory adverse events of cancer immunotherapy.
Dougan M; Luoma AM; Dougan SK; Wucherpfennig KW
Cell; 2021 Mar; 184(6):1575-1588. PubMed ID: 33675691
[TBL] [Abstract][Full Text] [Related]
14. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
Brockwell NK; Parker BS
Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches in cancer immunotherapy.
Subramaniam DS; Liu SV; Giaccone G
Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
[TBL] [Abstract][Full Text] [Related]
16. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.
Jacqueline C; Finn OJ
Semin Immunol; 2020 Feb; 47():101394. PubMed ID: 32273212
[TBL] [Abstract][Full Text] [Related]
17. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
18. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.
Tahir SA; Gao J; Miura Y; Blando J; Tidwell RSS; Zhao H; Subudhi SK; Tawbi H; Keung E; Wargo J; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22246-22251. PubMed ID: 31611368
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
